Xeris Biopharma Holdings, Inc. XERS Accrued returns reserve
Accrued returns reserve at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept xers:Accruedreturnsreserve.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s accrued returns reserve.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s accrued returns reserve?
- Xeris Biopharma Holdings, Inc. (XERS) reported accrued returns reserve of $18.72M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s accrued returns reserve changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s accrued returns reserve decreased by 5.0% year-over-year, from $19.7M to $18.72M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s accrued returns reserve?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s accrued returns reserve has grown at a 45.7% compound annual growth rate (CAGR), from $2.89M to $18.97M.
- What does accrued returns reserve mean?
- This liability represents the estimated value of products expected to be returned by customers, typically due to expiration or damage, for which revenue has already been recognized. It serves as a contra-revenue provision that accounts for the uncertainty inherent in product sales and distribution. A stable or declining reserve relative to sales may indicate effective inventory management and product quality control.